http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106414500-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2014-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106414500-B |
| titleOfInvention | anti-WT 1/HLA bispecific antibodies |
| abstract | Disclosed herein is a bispecific version of a T cell receptor mimetic (TCRm) mAb reactive with human immune effector cell antigen and WT1 peptide/HLA-a epitope. The antibody selectively binds to leukemia and solid tumor cells expressing WT1 and HLA-A and activated resting human T cells that release interferon- (IFN-. gamma.) and kill target cancer cells in vitro. Importantly, the antibodies mediate autologous T cell proliferation and targeted potent cytotoxicity against fresh ovarian cancer cells. 3 different WT1/HLA-A2 expressing human cancers (including diffuse Ph + Acute Lymphocytic Leukemia (ALL), diffuse acute myeloid leukemia or peritoneal mesothelioma) were used in NOD SCID SCID γ c * The in vivo therapeutic activity of the antibodies was demonstrated in (NSG) mice. Mice receiving the antibodies and T cells also showed longer survival and delayed acroparalysis in both leukemia xenograft models. Also provided are methods of stimulating a primary T cell response comprising stimulating cytotoxic T cells against a first tumor antigen and a secondary T cell response comprising stimulating cytotoxic T cells against a first tumor antigen using the bispecific antibodies described hereinAn antigen and/or effector T cells and/or memory T cells directed against a second tumor antigen. |
| priorityDate | 2013-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 163.